United Therapeutics (UTH) AI Stock Analysis

Company Guidance

On the call management outlined near‑term and medium‑term guidance anchored by concrete metrics: Q2 2026 total revenue was about $783 million (essentially flat with Q1) with Tyvaso sales of $453 million; the company said starts, referrals, total patients and commercial patients all reached record levels exiting the quarter and the sales force was roughly doubled with new reps in the field by July 1 to deepen community reach; management is not reaffirming 2026 revenue guidance but expects H2 2026 to be stronger than H1 2026 and still sees a path (albeit narrowed) to a previously projected ~$4 billion revenue run rate by end‑2027; regulatory and development milestones include late‑June submission of the Tyvaso IPF sNDA (priority review possible — 6‑month review vs. 10‑month standard), an NDA for ralinepag in PAH (recently submitted), planned filings later this year for a ralinepag DPI IND and a treprostinil SMI NDA, projected potential approvals in 2027 for nebulized Tyvaso in IPF, ralinepag in PAH and the SMI device in PAH/PH‑ILD, TETON‑PPF enrollment ~95%+ and a Phase III readout expected in H2 2027, ADVANCE OUTCOMES and TETON‑1/2 were positive, UKidney EXPAND’s initial six‑patient cohort expected to complete this year with UThymoKidney EXTEND and EXPRESS‑UHeart progressing, and two additional commercial‑scale DPFs in Minnesota and Texas slated for completion by year‑end.